Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Biphenotypic, Acute 1Down Syndrome 1

Interventions

enzalutamide 21Magnetic Resonance Spectroscopy 21apalutamide 17Androgen Antagonists 14Specimen Handling 13Prednisone 13Abiraterone Acetate 13abiraterone 9Docetaxel 9Radiotherapy 8Biopsy 8darolutamide 7Radiosurgery 7Pluvicto 7Nivolumab 7cabazitaxel 6Lutetium-177 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6Lutetium 5radium Ra 223 dichloride 4pembrolizumab 4niraparib 4gallium 68 PSMA-11 4cabozantinib 4bicalutamide 4atezolizumab 4Watchful Waiting 4Surveys and Questionnaires 4Standard of Care 4Radiotherapy, Intensity-Modulated 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × deltacortene × 30 days × Clear all
NCT04947254 2026-05-15

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡